Skip to main content
. 2023 Feb 3;7(13):3117–3127. doi: 10.1182/bloodadvances.2022009411

Figure 2.

Figure 2.

OS. (A) OS for patients in the full analysis population (N = 153). (B) OS for patients in the efficacy-evaluable population with CR/CRh (n = 51), other responders (n = 20), and nonresponders (n = 76). Other responders are patients with CRi, PR, or MLFS. Nonresponders are patients in response assessment categories other than CR/CRh, CRi, PR, and MLFS.